Merck & Co., Inc. Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Remeasurement due to Settlement
Merck & Co., Inc. (MRK) reported Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Remeasurement due to Settlement of $34.00 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2024-11-06.
Financial Statements › Notes › Compensation Related Costs
us-gaap:DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement · last filed 2024-11-06
- Merck & Co., Inc. defined benefit plan, benefit obligation, (increase) decrease for remeasurement due to settlement for the quarter ending 2023-09-30 was $34.00M.
- Merck & Co., Inc. defined benefit plan, benefit obligation, (increase) decrease for remeasurement due to settlement for the quarter ending 2023-06-30 was $0.00.
- Merck & Co., Inc. defined benefit plan, benefit obligation, (increase) decrease for remeasurement due to settlement for the quarter ending 2023-03-31 was -$47.00M.
- Merck & Co., Inc. defined benefit plan, benefit obligation, (increase) decrease for remeasurement due to settlement for the quarter ending 2022-09-30 was -$296.00M.
| Period end | Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Remeasurement due to Settlement | Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Remeasurement due to Settlement 1 month | Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Remeasurement due to Settlement 3 month | Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Remeasurement due to Settlement 3 month as first filed | Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Remeasurement due to Settlement 6 month | Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Remeasurement due to Settlement 9 month |
|---|---|---|---|---|---|---|
| 2023-09-30 | $34.00M 10-Q · filed 2024-11-06 | $34.00M derived: sum of 2 quarters · filed 2024-11-06 | -$13.00M 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$47.00M 10-Q · filed 2023-08-07 | ||||
| 2023-03-31 | -$47.00M 10-Q · filed 2024-08-05 | -$44.00M 10-Q · filed 2023-05-05 | ||||
| 2022-09-30 | -$296.00M 10-Q · filed 2022-11-03 | -$131.00M 10-Q · filed 2022-11-03 | ||||
| 2022-06-30 | $165.00M 10-Q · filed 2022-08-05 | |||||
| 2021-09-30 | -$160.00M 10-Q · filed 2021-11-05 | |||||
| 2021-06-02 | $1.70B 10-Q · filed 2021-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |